Amendment to collaborative research to identify therapeutic agents to control misregulated cell cycle transitions in tumor cells, vascular smooth muscle cells and other pathological conditions, with exclusive patent, know-how and technology cross-license to make, have made, use, sell and sublicense compounds and products that licensee developed independently | NobleID
v1
Amendment to collaborative research to identify therapeutic agents to control misregulated cell cycle transitions in tumor cells, vascular smooth muscle cells and other pathological conditions, with exclusive patent, know-how and technology cross-license to make, have made, use, sell and sublicense compounds and products that licensee developed independently.
